Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intravitreal Bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Bevacizumab is a monoclonal antibody that binds all isomers of vascular endothelial growth factor (VEGF). When administered intravitreally (IVB), it is used to treat various eye conditions including diabetic macular edema (DME) and neovascular age-related macular degeneration (ARMD). IVB works by preventing the growth of certain types of blood vessels to abnormal tissues, decreasing the growth of these tissues by starving the cells of nutrients needed to grow. The typical dose for intravitreal injection is 1.25 mg.
- Brand names
- AvastinMvasiZirabevAlymsysAvziviVegzelmaBambeviAbevmyAybintio
- Other names
- IVB
02
Targets
Beyond the preview
Go deeper on Intravitreal Bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intravitreal Bevacizumab.